HP
SIOX

Hound Partners’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Hound Partners’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-50,000
Closed -$398K – 36
2018
Q4 		$398K Buy
+50,000
New +$721K 0.01% 27

Other funds holding SIOX

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Hound Partners's SIOX Position: Q1 2019 in Review

Hound Partners sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2019, closing a stake of 50,000 shares — an estimated $398K sold.

Hound Partners first reported a position in SIOX in Q4 2018 and held it in 1 quarter. The position peaked at $398K in Q4 2018. 57 funds tracked by Wall St. Rank hold SIOX as of Q1 2019.

  • Hound Partners reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Hound Partners sold 50,000 Sio Gene Therapies Inc. Common Stock shares in Q1 2019, an estimated $398K.
  • Hound Partners first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Hound Partners's Sio Gene Therapies Inc. Common Stock position peaked at $398K in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2019.

Based on Hound Partners's 13F filing for Q1 2019, filed 15 May 2019.